Ovidrel 250 mcg (Choriogonadotropin Alfa SOLUTION) 250 MCG

OVIDREL 250 MCG is a subcutaneous solution containing choriogonadotropin alfa, used in reproductive health. This medication supports ovulation induction and is available in a 0.5ml pack size.

Strength

250 MCG

Pack Size

0.5ML

Manufacturer / TM Owner

EMD SERONO, A DIVISION OF EMD INC., CANADA

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

OVIDREL 250 MCG is primarily used to trigger ovulation in assisted reproductive techniques. It mimics the natural luteinizing hormone, aiding in the maturation and release of eggs. This solution is often part of fertility treatments, helping to coordinate the timing of ovulation for procedures like in vitro fertilization (IVF).

Side Effects

Common effects of OVIDREL 250 MCG may include mild injection site reactions, such as redness or swelling. Some users might experience headaches or abdominal discomfort. These effects are generally temporary and should be discussed with a healthcare provider if they persist or worsen.

Precautions & Warnings

OVIDREL 250 MCG should be handled with care, ensuring proper storage and administration. It is important to follow the prescribed guidelines for subcutaneous injection. Users should be aware of potential allergic reactions and seek immediate medical attention if severe symptoms occur.

Avoid Interactions

OVIDREL 250 MCG may interact with other medications, particularly those affecting hormone levels. It is advisable to inform healthcare providers about all current medications, including supplements. Alcohol and certain drugs may influence the effectiveness or safety of this solution.

Frequently Asked Questions

OVIDREL 250 MCG is used to trigger ovulation in fertility treatments, helping to coordinate the release of eggs.

OVIDREL 250 MCG is administered via subcutaneous injection, typically into the abdominal area.

Common side effects may include injection site reactions, headaches, and abdominal discomfort.

Potential interactions with other medications should be discussed with a healthcare provider to ensure safety.

Seek immediate medical attention if severe reactions, such as allergic symptoms, occur after using OVIDREL 250 MCG.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.